Trial Outcomes & Findings for Evaluate Clinical Research From Commerical Oral Care Products (NCT NCT00759187)
NCT ID: NCT00759187
Last Updated: 2010-03-04
Results Overview
Scale 0 to 5 (zero= no plaque to 5 = plaque covering 2/3 or more of the crown of the tooth)
Recruitment status
COMPLETED
Study phase
PHASE3
Target enrollment
25 participants
Primary outcome timeframe
4-Day
Results posted on
2010-03-04
Participant Flow
At clinical site
Participant milestones
| Measure |
Fluoride
|
Fluoride/Triclosan
|
Chlorhexidine Gluconate
|
|---|---|---|---|
|
Overall Study
STARTED
|
8
|
8
|
9
|
|
Overall Study
COMPLETED
|
8
|
8
|
9
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Evaluate Clinical Research From Commerical Oral Care Products
Baseline characteristics by cohort
| Measure |
Fluoride
n=8 Participants
|
Fluoride/Triclosan
n=8 Participants
|
Chlorhexidine Gluconate
n=9 Participants
|
Total
n=25 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
8 Participants
n=5 Participants
|
8 Participants
n=7 Participants
|
9 Participants
n=5 Participants
|
25 Participants
n=4 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Age Continuous
|
29.4 years
STANDARD_DEVIATION 6.9 • n=5 Participants
|
32.6 years
STANDARD_DEVIATION 8.8 • n=7 Participants
|
33.1 years
STANDARD_DEVIATION 9.0 • n=5 Participants
|
31.8 years
STANDARD_DEVIATION 8.1 • n=4 Participants
|
|
Sex: Female, Male
Female
|
8 Participants
n=5 Participants
|
7 Participants
n=7 Participants
|
8 Participants
n=5 Participants
|
23 Participants
n=4 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
|
Region of Enrollment
United States
|
8 participants
n=5 Participants
|
8 participants
n=7 Participants
|
9 participants
n=5 Participants
|
25 participants
n=4 Participants
|
PRIMARY outcome
Timeframe: 4-DayScale 0 to 5 (zero= no plaque to 5 = plaque covering 2/3 or more of the crown of the tooth)
Outcome measures
| Measure |
Fluoride
n=9 Participants
|
Fluoride/Triclosan
n=8 Participants
|
Chlorhexidine Gluconate
n=8 Participants
|
|---|---|---|---|
|
Dental Plaque Index
|
2.79 Units on a scale
Standard Deviation 0.37
|
2.82 Units on a scale
Standard Deviation 0.39
|
1.99 Units on a scale
Standard Deviation 0.41
|
Adverse Events
Fluoride
Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths
Fluoride/Triclosan
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
Chlorhexidine Gluconate
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Fluoride
n=9 participants at risk
|
Fluoride/Triclosan
n=8 participants at risk
|
Chlorhexidine Gluconate
n=8 participants at risk
|
|---|---|---|---|
|
General disorders
Canker sore
|
11.1%
1/9 • Number of events 1 • 4 day treatment period
|
0.00%
0/8 • 4 day treatment period
|
0.00%
0/8 • 4 day treatment period
|
|
General disorders
Cold symptoms
|
44.4%
4/9 • Number of events 4 • 4 day treatment period
|
0.00%
0/8 • 4 day treatment period
|
0.00%
0/8 • 4 day treatment period
|
|
General disorders
Conjunctivitis
|
11.1%
1/9 • Number of events 1 • 4 day treatment period
|
0.00%
0/8 • 4 day treatment period
|
0.00%
0/8 • 4 day treatment period
|
|
General disorders
Heavy menstrual bleeding
|
0.00%
0/9 • 4 day treatment period
|
12.5%
1/8 • Number of events 1 • 4 day treatment period
|
0.00%
0/8 • 4 day treatment period
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: GT60